Summary of Key Points Core Viewpoint - Multiple companies conducted share buybacks on September 11, 2025, with Tencent Holdings leading in both the number of shares repurchased and the total amount spent [1][2]. Company Buyback Details - Tencent Holdings (00700) repurchased 874,000 shares for a total of 550 million, with a year-to-date total of 54.758 million shares, representing 0.596% of its total share capital [2]. - Hang Seng Bank (00011) repurchased 210,000 shares for 24.882 million, with a year-to-date total of 6.12 million shares, representing 0.325% of its total share capital [2]. - Stone Four Pharmaceutical Group (02005) repurchased 6 million shares for 18.1433 million, with a year-to-date total of 22.6 million shares, representing 0.766% of its total share capital [2]. - MGM China (02282) repurchased 1 million shares for 16.2463 million, with a year-to-date total of 18.6274 million shares, representing 0.490% of its total share capital [2]. - Other notable companies include: - China Hongqiao (01378) with 100,500 shares repurchased for 2.4636 million, totaling 149 million shares, representing 1.590% of its total share capital [2]. - Weigao Group (01066) with 429,200 shares repurchased for 2.4248 million, totaling 10.4532 million shares, representing 2.315% of its total share capital [2]. - Coolpad Group (02369) with 924,000 shares repurchased for 1.2036 million, totaling 1.2519 million shares, representing 3.057% of its total share capital [2].

Company News - New天绿色能源 (00956.HK) reported a power generation of 9.8787 million MWh in the first eight months, an increase of 10.55% year-on-year; August's power generation was 784.8 thousand MWh, up 23.53% year-on-year [2] -远洋集团 (03377.HK) recorded a contract sales amount of 16.44 billion yuan in the first eight months, a decrease of 25.9% year-on-year; August's contract sales were approximately 1.7 billion yuan, down 17.5% year-on-year [2] - 合生创展集团 (00754.HK) reported a contract sales amount of approximately 9.902 billion yuan in the first eight months, a decrease of 15.6% year-on-year; August's contract sales were about 334 million yuan, down 38.4% year-on-year [2] - 越秀交通基建 (01052.HK) reported a cumulative toll revenue of approximately 603 million yuan for the Guangzhou North Second Ring Expressway in the first seven months, a decrease of 0.7% year-on-year [2] - 华油能源 (01251.HK) entered into a financing lease agreement with Zhongguancun Science and Technology Leasing [2] - 日清食品 (01475.HK) plans to invest 30.68 million yuan to acquire land in Zhuhai for new production facilities [2] - 鲁大师 (03601.HK) subscribed to a structured deposit product from China Merchants Bank, involving 50 million yuan [2] - 越秀地产 (00123.HK) plans to obtain a term loan financing of 200 million HKD [2] - 康宁杰瑞制药-B (09966.HK) had its new drug application for KN026 (Anituzumab injection) accepted by the National Medical Products Administration [2] Buyback Activities - 腾讯控股 (00700.HK) repurchased 874,000 shares at a cost of 550 million HKD, with repurchase prices ranging from 624 to 633 HKD [2] - 汇丰控股 (00005.HK) spent approximately 108 million HKD to repurchase about 1.041 million shares, with repurchase prices between 102.8 and 104.3 HKD [2] - 恒生银行 (00011.HK) repurchased 210,000 shares at a cost of approximately 24.882 million HKD, with repurchase prices from 117.9 to 119.2 HKD [2] - 百胜中国 (09987.HK) repurchased about 57,900 shares at a cost of approximately 20.2 million HKD, with repurchase prices between 347 and 351.8 HKD [2] - 石四药集团 (02005.HK) repurchased 6 million shares at a cost of approximately 18.143 million HKD, with repurchase prices ranging from 2.98 to 3.04 HKD [2] - 美高梅中国 (02282.HK) repurchased 1 million shares at a cost of 16.2463 million HKD, with repurchase prices between 16.04 and 16.45 HKD [3] Power Generation Data - 中广核新能源 (01811.HK) reported a power generation of approximately 12,850.5 GWh in the first eight months, a decrease of 1.6% year-on-year; August's power generation was 1,543.7 GWh, down 5.7% year-on-year [4]

（原标题：石四药集团(02005.HK)9月11日回购600.00万股，耗资1814.33万港元） | 日期 | 回购股数 （万股） | 回购最高价 （港元） | 回购最低价 （港元） | 回购金额 （万港元） | | --- | --- | --- | --- | --- | | 2025.09.11 | 600.00 | 3.040 | 2.980 | 1814.33 | | 2025.06.05 | 540.00 | 2.800 | 2.770 | 1509.58 | | 2025.06.04 | 345.00 | 2.850 | 2.790 | 972.54 | | 2025.06.02 | 755.00 | 2.780 | 2.610 | 2098.38 | | 2025.04.02 | 280.00 | 3.440 | 3.330 | 958.82 | | 2025.01.16 | 50.00 | 3.210 | 3.190 | 160.11 | | 2025.01.15 | 160.00 | 3.230 | 3.190 | 513.20 | | 2025.01.14 | 70.00 | 3.25 ...

格隆汇9月11日丨石四药集团(02005.HK)发布公告，2025年9月11日耗资1814.33万港元回购600万股，回 购价格每股2.98-3.04港元。 ...

石四药集团(02005)发布公告，于2025年9月11日，该公司斥资1814.33万港元回购600万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 石四藥集團有限公司 呈交日期： 2025年9月11日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02005 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事 ...

备注：持股数变动有可能因供股、合股、拆股等情况引起，请注意对照实际情况进行辨别。 智通财经APP获悉，华信地产财务(00252)、石四药集团(02005)、汇量科技(01860)于2025年9月11日进行 了最新股东权益披露。 | 股票名称 | 机构名称 | 性质 | 变动前持股 | 变动后持股 | 持股比 | | --- | --- | --- | --- | --- | --- | | 华信地产财务 | 蔡乃端 | 好仓 | 1.06 亿股 | 1.06 亿股 | 47.02%(最新) | | (00252) | | | | | 47.02%(前次) | | 石四药集团 | 曲继广 | 好仓 | 11.73 亿股 | 11.74 亿股 | 39.78%(最新) | | (02005) | | | | | 39.75%(前次) | | 汇量科技 | 宋笑飞 | 好仓 | 289.24 万股 | 219.24 万股 | 0.14%(最新) | | (01860) | | | | | 0.18%(前次) | | 石四药集团 | China Pharmaceutical | 好仓 | 8.82 亿股 | 8.83 ...

格隆汇9月10日丨根据联交所最新权益披露资料显示，2025年9月9日，石四药集团(02005.HK)获执行董事兼主席兼行政总裁曲继广在场内以每股均3.1865港 元增持103万股，涉资约328.21万港元。 增持后，曲继广最新持股数目为1,173,212,000股，持股比例由39.72%上升至39.75%。 | 股份代號: | 02005 | | --- | --- | | 上市法國名稱: | 石四藥集國有限 | | 日期 (日 / 月 / 年): | 10/08/2025 - 10 | | 表格序號 | | 大股東/董事/最高行政人員名 作出披露的 買入 / 賣出或涉及的 每股的平均價 | | | | | 持有權益的股份數目 佔已發行的 有關事件的日期 相 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 泉内 | 股份數目 | | | 福多問上述** | 有投票權股 (日 / 月 / 年) | | | | | | | | | 份自分比 | | | | | | | | | 96 | | CS20250909E00293 | China Pha ...

Core Viewpoint - The company Shijiazhuang Pharmaceutical Group (stock code: 02005) has received approval from the National Medical Products Administration of China for its indocyanine green to be used as an active pharmaceutical ingredient in marketed formulations [1] Group 1 - Indocyanine green is utilized for diagnosing various liver diseases, including cirrhosis, liver fibrosis, and drug-induced liver injury, as well as assessing liver damage and reserve function [1] - The compound is also applicable for choroidal vascular angiography to identify the location of choroidal disorders [1]

智通财经APP讯，石四药集团(02005)公布，该集团的吲哚菁绿已获中国国家药品监督管理局批准登记成 为在上市制剂使用的原料药。 吲哚菁绿可用于诊断肝硬化、肝纤维化、韧性肝炎、职业和药物中毒性肝病等各种肝脏疾病，了解肝脏 的损害程度及其储备功能; 亦可用于脉络膜血管造影，确定脉络膜疾患的位置。 ...